Cancer Immune Therapy Edited by G. Stuhler and P. Walden ...

142 7 Immunosuppresive Factors in Cancer
sis in a murine high-grade glioma
model. Cancer Res. 58: 302.
99 Moore, K. W., R. de Waal Malefyt,
R. L. Coffman and A. O'Garra. 2001.
Interleukin-10 and the interleukin-10
receptor. Annu. Rev. Immunol. 19: 683.
100 Fiorentino, D. F., M. W. Bond and
T. R. Mosmann. 1989. Two types of
mouse T helper cell. IV. Th2 clones secrete
a factor that inhibits cytokine production
by T h1 clones. J. Exp. Med. 170:
2081.
101 Becker, J. C., C. Czerny and
E. B. Brocker. 1994. Maintenance of
clonal anergy by endogenously produced
IL-10. Int. Immunol. 6: 1605.
102 Ortegel, J. W., E. D. Staren, L. P. Faber,W.
H. Warren and D. P. Braun.
2000. Cytokine biosynthesis by tumorinfiltrating
T lymphocytes from human
non-small-cell lung carcinoma. Cancer
Immunol. Immunother. 48: 627.
103 Cooper, M. A., T. A. Fehniger,
S. C. Turner, K. S. Chen, B. A. Ghaheri,
T. Ghayur,W. E. Carson and
M. A. Caligiuri. 2001. Human natural
killer cells: a unique innate immunoregulatory
role for the CD56(bright) subset.
Blood 97: 3146.
104 Loercher, A. E., M. A. Nash, J. J. Kavanagh,
C. D. Platsoucas and R. S. Freedman.
1999. Identification of an IL-10producing
HLA-DR-negative monocyte
subset in the malignant ascites of patients
with ovarian carcinoma that inhibits
cytokine protein expression and proliferation
of autologous Tcells. J. Immunol.
163: 6251.
105 Huang, M., S. Sharma, J. T. Mao and
S. M. Dubinett. 1996. Non-small cell
lung cancer-derived soluble mediators
and prostaglandin E2 enhance peripheral
blood lymphocyte IL-10 transcription
and protein production. J. Immunol.
157: 5512.
106 Sato, T., P. McCue, K. Masuoka,
S. Salwen, E. C. Lattime, M. J. Mastrangelo
and D. Berd. 1996. Interleukin
10 production by human melanoma.
Clin. Cancer Res. 2: 1383.
107 Huettner, C., S. Czub, S. Kerkau,
W. Roggendorf and J. C. Tonn. 1997.
Interleukin 10 is expressed in human
gliomas in vivo and increases glioma
cell proliferation and motility in vitro.
Anticancer Res. 17: 3217.
108 Mori, N. and D. Prager. 1998. Interleukin-10
gene expression and adult Tcell
leukemia. Leuk. Lymph. 29: 239.
109 Bargou, R. C., M. Y. Mapara,
C. Zugck, P. T. Daniel, M. Pawlita,
H. Dohner and B. Dorken. 1993.
Characterization of a novel Hodgkin
cell line, HD-MyZ, with myelomonocytic
features mimicking Hodgkin's disease
in severe combined immunodeficient
mice. J. Exp. Med. 177: 1257.
110 Voorzanger, N., R. Touitou, E. Garcia,
H. J. Delecluse, F. Rousset,
I. Joab, M. C. Favrot and J. Y. Blay.
1996. Interleukin (IL)-10 and IL-6 are
produced in vivo by non-Hodgkin's lymphoma
cells and act as cooperative
growth factors. Cancer Res. 56: 5499.
111 Matsuda, M., F. Salazar, M. Petersson,
G. Masucci, J. Hansson, P. Pisa,
Q. J. Zhang, M. G. Masucci and
R. Kiessling. 1994. Interleukin 10 pretreatment
protects target cells from tumor-
and allo-specific cytotoxic T cells
and downregulates HLA class I expression.
J. Exp. Med. 180: 2371.
112 Salazar-Onfray, F., M. Petersson,
L. Franksson, M. Matsuda, T. Blankenstein,
K. Karre and R. Kiessling.
1995. IL-10 converts mouse lymphoma
cells to a CTL-resistant, NK-sensitive
phenotype with low but peptide-inducible
MHC class I expression. J. Immunol.
154: 6291.
113 Tsuruma, T., A. Yagihashi, K. Hirata,
T. Torigoe, J. Araya, N. Watanabe and
N. Sato. 1999. Interleukin-10 reduces
natural killer (NK) sensitivity of tumor
cells by downregulating NK target
structure expression. Cell. Immunol.
198: 103.
114 Alas, S., C. Emmanouilides and B. Bonavida.
2001. Inhibition of interleukin
10 by rituximab results in down-regulation
of bcl-2 and sensitization of B-cell
non-Hodgkin's lymphoma to apoptosis.
Clin. Cancer Res. 7: 709.
115 Bohlen, H., M. Kessler, M. Sextro,
V. Diehl and H. Tesch. 2000. Poor clinical
outcome of patients with Hodgkin's
disease and elevated interleukin-10
serum levels. Clinical significance of in-